Rezolute Inc RZ402 Phase 2 clinical program - Corporate Call Transcript
Good afternoon. I'm Nevan Elam, Rezolute's Founder and CEO. Before we begin, as a reminder, the information discussed during this call will include forward-looking statements which represent the company's view as of today, March 22nd, 2023. We undertake no obligation to update or revise any forward-looking statements to reflect new information or future events except as required by law. Please refer to our filings with the SEC for information concerning risks and risk factors that are there as well that could cause actual results to differ materially from those expressed or implied by these statements.
Thank you for joining us today for an in-depth discussion of our program, RZ402, an oral plasma kallikrein inhibitor being studied as a potential therapy to treat diabetic macular edema. Participating in the discussion, we are fortunate to have Dr. Bob Bhisitkul, Professor of Clinical Ophthalmology and Retinal Specialist at the University of California, San Francisco, and a member of our Scientific Advisory Board. Dr. Bhisitkul brings a unique and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |